Isoxazole derivatives as mutant isocitrate dehydrogenase 1 inhibitors
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- DAIICHI SANKYO CO LTD
- Publication Date
- 2020-06-26
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to a compound having excellent inhibitory activity against mutant isocitrate dehydrogenase 1 (hereinafter also referred to as "IDH1") and a pharmaceutically acceptable salt thereof. Background technique
[0002] Isocitrate dehydrogenases (IDHs: isocitrate dehydrogenases) are a group of enzymes that convert isocitrate into 2-oxoglutarate (α-ketoglutarate). This group of enzymes can be further subdivided into NAD+-dependent isocitrate dehydrogenases (EC 1.1.1.41) and NADP+-dependent isocitrate dehydrogenases (EC 1.1.1.42).
[0003] IDH1 (isocitrate dehydrogenase 1 (NADP+), soluble) protein and IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial) protein are classified as NADP+-dependent isocitrate dehydrogenase (EC 1.1.1.42) enzymes. Mutations in the IDH1 gene or IDH2 gene are found in various cancers. Specific examples include glioma and glioblastoma, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferati...